September 28, 2010
Penn Medicine Joins Parkinson’s Progression Markers Initiative (PPMI) as Official Study Site and Bioanalytics Core Lead
$40-million, Five-Year Observational Clinical Study, Sponsored by Michael J. Fox Foundation, Seeks Biomarkers of Parkinson’s Disease
PHILADELPHIA – The Penn Medicine Parkinson’s Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson’s disease progression. Enrollment of 20 patients and 10 controls at the Penn Parkinson’s Disease and Movement Disorders Center is expected to begin in October 2010 and will continue for approximately two years.
“PPMI will provide invaluable data on the early Parkinson's disease process, laying the critical groundwork for breakthrough therapies that are aimed at the underlying mechanisms of disease,” said Matthew Stern, MD, professor of Neurology at the Perelman School of Medicine and director of the Penn Parkinson's Disease and Movement Disorders Center. “Penn Medicine has been at the forefront of Parkinson’s disease research and care for years. It is deeply meaningful to have been selected as a PPMI site and to have our commitment to speeding Parkinson’s solutions recognized.”
Said Michael J. Fox: “This is an ambitious undertaking, no doubt. But nothing worth having comes easily. Everything we’ve learned up to now, the partnerships we’ve worked to forge, the results of research we’ve funded — it’s all put us in position to launch this effort. We’re ready to roll up our sleeves and, hopefully, get this done.”
Biomarkers: Critical for Parkinson’s Drug Development
John Q. Trojanowski, MD, PhD, director of the Penn Udall Center for Parkinson's Research and Leslie M. Shaw, PhD, professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine will lead the PPMI Bioanalytics Core. They will be responsible for analyzing samples collected from all trial participants, using a test they designed, standardized and validated to measure levels of specific biomarkers in spinal fluid. Drs. Trojanowski and Shaw, who also serve as co-leaders of the Biomarker Core for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), will provide additional experience to consult with the PPMI Biorepository Core, to ensure the samples are collected and stored in a standardized way. In addition, they will be part of a collaborative group evaluating any novel diagnostic biomarkers that emerge in the course of the trial, to see if they can and should be integrated into the PPMI study.
“This bold cutting edge study addresses an important unmet need for development of better Parkinson’s disease diagnostics that will have as profound an impact on the diagnosis and treatment of Parkinson’s disease as the ADNI study is having now on Alzheimer’s disease,” said Dr. Trojanowski and Dr. Shaw. “Now is the time to move full speed ahead with PPMI. We applaud The Michael J. Fox Foundation for its vision and leadership with this project.”
A biomarker could be any objectively measurable physical characteristic associated with the presence of disease (diagnostic or risk marker) or any characteristic that changes over time in a way that can be tied to the progression of disease (progression marker).
“There is no doubt that finding a biomarker is critical to the development of next-generation therapies, and that the lack of this tool is among the most critical issues facing the PD research field,” said Katie Hood, CEO of The Michael J. Fox Foundation. “MJFF has funded biomarker discovery efforts for years. Now we are poised for a concerted, unified effort that will take these discoveries to the next level.”
The lack of a PD biomarker impedes PD diagnosis and treatment, and also critically stalls the development of improved therapies, particularly therapies to slow or stop the progression of PD, something no currently available treatment can do. Clinical trials of new, potentially disease-modifying Parkinson’s treatments are at risk of yielding inconclusive results, because there is no way to measure the effects of those treatments objectively.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.